BEST UNLIMITED TURBO LONG CERTIFICATE - BIOMARIN PHARMACEUTICAL Stock

Certificat

B432S

DE000SU1Q2E3

Market Closed - Euronext Paris 12:30:01 2024-05-20 pm EDT
0.31 EUR -22.50% Intraday chart for BEST UNLIMITED TURBO LONG CERTIFICATE - BIOMARIN PHARMACEUTICAL
Current month-55.84%
1 month-77.78%
Date Price Change
24-05-20 0.31 -22.50%
24-05-17 0.4 -4.76%
24-05-16 0.42 -40.00%
24-05-15 0.7 +11.11%
24-05-14 0.63 -14.86%

Real-time Euronext Paris

Last update May 20, 2024 at 12:30 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
B432S
ISINDE000SU1Q2E3
Date issued 2023-11-06
Strike 74.25 $
Maturity Unlimited
Parity 10 : 1
Emission price 1
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.705
Lowest since issue 0.2

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
77.05 USD
Average target price
109.3 USD
Spread / Average Target
+41.89%
Consensus
  1. Stock Market
  2. Certificates
  3. B432S Certificat
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW